Detalles de la búsqueda
1.
Lessons learned from postmarketing withdrawals of expedited approvals for oncology drug indications.
Lancet Oncol
; 25(3): e126-e135, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38423058
2.
Illustrating the financial consequences of outcome-based payment models from a payers perspective- the case of autologous gene therapy atidarsagene autotemcel (Libmeldy®).
Value Health
; 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38795960
3.
The Beneluxa Initiative domain task force health technology assessment: a comparison of member countries' past health technology assessments.
Int J Technol Assess Health Care
; 39(1): e44, 2023 Jun 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37317832
4.
Involvement of Patients and Medical Professionals in the Assessment of Relative Effectiveness: A Need for Closer Cooperation.
Value Health
; 25(9): 1480-1488, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550334
5.
Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
Eur J Cancer Care (Engl)
; 31(6): e13749, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300863
6.
Cost-Based Price Calculation of Mexiletine for Nondystrophic Myotonia.
Value Health
; 24(7): 925-929, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34243835
7.
Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements.
Int J Technol Assess Health Care
; 37(1): e83, 2021 Aug 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34424152
8.
Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib.
Eur J Clin Pharmacol
; 76(9): 1213-1226, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32488333
9.
Feasibility of and patients' perspective on nilotinib dried blood spot self-sampling.
Eur J Clin Pharmacol
; 75(6): 825-829, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30729257
10.
Adjuvant immune checkpoint blockade revisited.
Lancet Oncol
; 24(7): 717-719, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37414008
11.
Needs for information and reasons for (non)adherence in chronic myeloid leukaemia: Be aware of social activities disturbing daily routines.
Eur J Haematol
; 2018 Jul 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-30058149
12.
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform.
Lancet Oncol
; 23(2): 198-201, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35114116
13.
Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists.
BMC Cancer
; 17(1): 122, 2017 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28187759
14.
Author Reply.
Value Health
; 25(1): 158-159, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35031095
15.
Adherence to oral anticancer agents: Healthcare providers' perceptions, beliefs and shared decision making in Belgium and the Netherlands.
Acta Oncol
; 55(4): 437-43, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26959410
16.
Study protocol of the RAND-study: a multicenter, prospective cohort study investigating response and adherence to nilotinib treatment in chronic myeloid leukemia.
BMC Cancer
; 14: 247, 2014 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24712728
17.
Adherence and patients' experiences with the use of oral anticancer agents.
Acta Oncol
; 53(2): 259-67, 2014 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-24266637
18.
Satisfaction with information on nilotinib treatment in chronic myeloid leukemia patients.
Acta Oncol
; 58(6): 891-896, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30905234
19.
The impact of an 'evergreening' strategy nearing patent expiration on the uptake of biosimilars and public healthcare costs: a case study on the introduction of a second administration form of trastuzumab in The Netherlands.
Eur J Health Econ
; 2024 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38190008
20.
Systemic anticancer treatment in the Netherlands: Few hospitals treat many patients, many hospitals treat few patients.
Health Policy
; 135: 104865, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37459745